NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA) – Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that Hercules Technology Growth Capital, Inc. (“Hercules”) has exercised an option to participate in an exchange of US$0.5 million debt for common stock and warrants. Kamada also announced that it has completed the private allocation of common stock and warrants to a small group of new investors, resulting in gross proceeds to Kamada of approximately US$1.6 million. This concludes a series of financings that commenced February 23, 2009.
